Get the Stockscreener App
3.82
1.04%
-0.04
Pre-market:
3.83
0.01
+0.26%
Aquestive Therapeutics Inc stock is traded at $3.82, with a volume of 2.74M.
It is down -1.04% in the last 24 hours and down -2.30% over the past month.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
See More
Previous Close:
$3.86
Open:
$3.86
24h Volume:
2.74M
Relative Volume:
0.58
Market Cap:
$466.05M
Revenue:
$58.36M
Net Income/Loss:
$-25.72M
P/E Ratio:
-10.49
EPS:
-0.3641
Net Cash Flow:
$-24.91M
1W Performance:
-4.50%
1M Performance:
-2.30%
6M Performance:
-1.04%
1Y Performance:
+28.62%
1-Day Range:
$3.65
$3.90
1-Week Range:
$3.65
$4.18
52-Week Range:
$2.12
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Name
Aquestive Therapeutics Inc
Sector
Phone
908-941-1900
Address
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
3.82 | 470.93M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-10-24 | Initiated | Leerink Partners | Outperform |
| Apr-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Apr-22-19 | Initiated | H.C. Wainwright | Buy |
| Jan-03-19 | Initiated | Lake Street | Buy |
| Aug-20-18 | Initiated | JMP Securities | Mkt Outperform |
| Aug-20-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Aquestive Therapeutics Inc Stock (AQST) Latest News
Aquestive Therapeutics, Inc. (AQST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - PR Newswire
Aquestive Therapeutics Inc. (AQST) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Faruqi & Faruqi Investigates Aquestive Therapeutics for Investor Losses - intellectia.ai
Revenue Downgrade: Here's What Analysts Forecast For Aquestive Therapeutics, Inc. (NASDAQ:AQST) - 富途牛牛
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares May Have Slumped 36% But Getting In Cheap Is Still Unlikely - 富途牛牛
Aquestive Therapeutics price target lowered to $6 from $8 at Lake Street - Yahoo Finance
Federated Hermes Inc. Takes $4.38 Million Position in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Trimmed Their Revenue Forecasts By 26% - Yahoo Finance
Need To Know: The Consensus Just Cut Its Aquestive Therapeutics, Inc. (NASDAQ:AQST) Estimates For 2026 - simplywall.st
FDA CRL for Aquestive’s Anaphylm Comes With Clearer Path Forward - Citeline News & Insights
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics - Chartmill
Faruqi & Faruqi Investigates Aquestive Therapeutics After FDA Concerns - intellectia.ai
What Does the Market Think About Aquestive Therapeutics Inc? - Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc.AQST - Chartmill
Leerink sees ‘silver lining’ in Aquestive CRL given defined path to approval - Yahoo Finance
H.C. Wainwright reiterates Buy rating on Aquestive stock after FDA response By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Buy rating on Aquestive stock after FDA response - Investing.com India
Does Aquestive Therapeutics (AQST) FDA Packaging Setback Reframe the Risk‑Reward in Its Allergy Franchise? - Yahoo Finance
Assessing Aquestive Therapeutics (AQST) Valuation After The FDA Complete Response Letter For Anaphylm - simplywall.st
US FDA declines to approve Aquestive’s oral drug for allergic reactions - WHTC
Aquestive receives FDA CRL for Anaphylm allergic reaction treatment - Yahoo Finance
FDA Issues Complete Response Letter to Aquestive Therapeutics for Anaphylm NDA Targeting Severe Allergic Reactions - geneonline.com
Oppenheimer Maintains Outperform on AQST Aquestive Therapeutics Feb 2026 - Meyka
FDA issues complete response letter for Aquestive’s anaphylaxis drug By Investing.com - Investing.com Nigeria
FDA Flags Administration Concerns for Aquestive's Noninvasive Epinephrine Film - The American Journal of Managed Care® (AJMC®)
Buy Rating Reaffirmed on Aquestive Therapeutics as Operational FDA Setbacks De-Risk Anaphylm’s Path to Approval - TipRanks
Regulatory clarity lifts Aquestive despite CRL for Anaphylm - BioWorld MedTech
Aquestive jumps despite receiving FDA Complete Response Letter - Seeking Alpha
Key facts: Aquestive Therapeutics stock rises 44% after FDA setback - TradingView
FDA knock-backs send shares in Pharming down, Aquestive up - FirstWord Pharma
Alliance Global sees Aquestive’s Anaphylm CRL as fixable, reiterates Buy rating - TipRanks
AQST Investors Have Opportunity to Join Aquestive Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - The AI Journal
Aquestive Therapeutics Target of Unusually High Options Trading (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics Gets FDA CRL for Anaphylm, Eyes Q3 Resubmission After Human Factors Fixes - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Shares Gap UpStill a Buy? - MarketBeat
Aquestive Therapeutics Stock Surges 43% Over Complete Response Letter From FDA For Anaphylm NDA - Nasdaq
With FDA rejections, Aquestive's shares go up, while Pharming's go down - Fierce Pharma
Aquestive leaps, despite receiving CRL for Anaphylm NDA - The Pharma Letter
FDA rejects Aquestive’s allergy drug over packaging issues - Endpoints News
AQST: FDA requires new human factors and PK studies for Anaphylm; resubmission expected by Q3 - TradingView
Aquestive Therapeutics Strives Amid Market Challenges - StocksToTrade
AQUESTIVE THERAPEUTICS, INC. (AQST) Stock, Price, News, Quotes, Forecast and Insights - MSN
AQST: FDA requires additional human factors and PK studies for Anaphylm, with resubmission planned for Q3 2024 - TradingView
AQUESTIVE THERAPEUTICS, INC. (AQST) - MSN
Aquestive Receives CRL For Anaphylm NDA; Deficiencies Limited To Packaging, Administration - Nasdaq
FDA issues complete response letter for Aquestive’s anaphylaxis drug - Investing.com
Aquestive stock rises despite FDA complete response letter for Anaphylm By Investing.com - Investing.com Australia
Aquestive stock rises despite FDA complete response letter for Anaphylm - Investing.com
FDA Issues Complete Response Letter on Anaphylm Application - TipRanks
Aquestive Therapeutics announces FDA issuance of Complete Response Letter for Anaphylm - marketscreener.com
Aquestive Therapeutics Inc Stock (AQST) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):